Fluticasone furoate/vilanterol - GSK/Innoviva
Alternative Names: '444/'698; 444/698; Breo Ellipta; FF/GW642444; FF/VI; Fluticasone furoate/GW642444; Fluticasone furoate/vilanterol trifenatate; Fluticasone-furoate/vilanterol; GSK-2285997; GW642444/GW685698; GW642444M/GW685698X; GW685698/GW642444; GW685698X/GW642444M; Relovair; Relvar Ellipta; RELVAR®/BREO® ELLIPTA®; Revinty ElliptaLatest Information Update: 05 Nov 2023
At a glance
- Originator GlaxoSmithKline; Theravance
- Developer GSK; Innoviva
- Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorobenzenes; Ethers; Glucocorticoids; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 19 May 2023 Efficacy and adverse events data from a phase III trial in Asthma presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
- 21 Mar 2022 GlaxoSmithKline completes a phase III trial in Asthma (In children, In adolescents) in the US, Argentina, China, Canada, Japan, Mexico, Romania, Russia, South Africa, Poland, Lithuania, Hungary, Bulgaria, Italy, Germany, and Spain (Inhalation) in March 2022 (EudraCT2016-004086-87) (NCT03248128)
- 14 May 2021 Interim efficacy data from a phase III CAPTAIN trial in Asthma presented 117th International Conference of the American Thoracic Society